THE WOODLANDS, Texas, June 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $19.00 per share, before underwriting discounts and other offering expenses. The gross proceeds from the sale of the shares, before underwriting discounts and other offering expenses, are expected to be $71.25 million. The offering is expected to close on June 25, 2013, subject to customary closing conditions. Repros Therapeutics has also granted the underwriters a 30-day option to purchase up to 562,500 additional shares of common stock. All of the shares in the offering are to be sold by Repros Therapeutics Inc. In connection with this offering, BofA Merrill Lynch is acting as the sole book-running manager and Lazard Capital Markets LLC, Ladenburg Thalmann & Co. Inc. and Ascendiant Capital Markets, LLC are acting as co-managers. The securities described above are being offered by Repros Therapeutics pursuant to a shelf registration statement filed by Repros Therapeutics with the Securities and Exchange Commission (SEC) and declared effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction. The offering may be made only by means of a prospectus supplement and accompanying base prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. A preliminary prospectus supplement related to the offering was filed with the SEC on June 17, 2013 and a final prospectus supplement relating to the offering will be filed with the SEC and will be available, free of charge, on the SEC's website located at www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from the offices of: BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attention: Prospectus Department or by emailing email@example.com. About Repros Therapeutics Inc. Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.